JAMIE JOHANSEN | AgWired | June 21, 2016
Just last year the small team raised their first round of funding and brought on CEO, Aaron Gilbertie, to help lead the company through the development, product registration and commercialization of Aptimmune’s vaccines. I met Aaron during the recent World Pork Expo and sat down with him to learn more. “Today we are primarily focused on two viral pathogens Porcine Reproductive and Respiratory Syndrome (PRRS) virus and influenza. The two most costly pathogens affecting pigs today.”